10 Best NASDAQ Stocks Under $5 to Buy Right Now
On April 28, Gabelli's John Belton joined 'Closing Bell Overtime' on CNBC to discuss how market expectations and overall investor sentiment have improved recently.
Palisade Bio Inc. (PALI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Octagon Capital Advisors Ting Jia | 10,276,317 | $17,983,555 | +8% | 1.99% |
| 2. | Perceptive Advisors Joseph Edelman | 8,928,149 | $15,624,261 | -26% | 0.31% |
| 3. | Commodore Capital Egen Atkinson And Michael Kramarz | 7,181,062 | $12,566,859 | -38% | 0.73% |
| 4. | RA Capital Management Peter Kolchinsky | 7,124,116 | $12,467,203 | 0.13% | |
| 5. | Eversept Partners Kamran Moghtaderi | 4,987,499 | $8,728,123 | -8% | 0.46% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.96 | 25,000 | $48,900.00 | 461,904 | 2026-07-09 | Filing | |
| $1.99 | 20,000 | $39,798.00 | 436,904 | 2026-07-08 | Filing | |
| $2.03 | 30,000 | $61,044.00 | 416,904 | 2026-07-07 | Filing | |
| $2.05 | 20,000 | $41,040.00 | 386,904 | 2026-07-06 | Filing | |
| $1.98 | 10,000 | $19,800.00 | 366,904 | 2026-07-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.05 | 51,880 | $106,535.58 | 94,009 | 2026-07-07 | Filing | |
| $2.07 | 146,798 | $303,343.39 | 217,555 | 2026-07-07 | Filing | |
| $1.75 | 1,989 | $3,480.75 | 13,263 | 2026-02-12 | Filing | |
| $1.75 | 3,896 | $6,818.00 | 27,353 | 2026-02-12 | Filing | |
| $0.64 | 300 | $192.00 | 0 | 2023-09-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 450,543 | $941,635 | 0.01% | |
| 2. | 29,228 | $33,247 | 0% | |
| 3. | 12,203 | $24,040 | 0% | |
| 4. | 8,500 | $17 | 0.01% | |
| 5. | 0 | $0 | 0% |
News See All
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile
TheFly reported on April 8 that Wolfe Research initiated coverage of PALI with an Outperform rating and a $7 price target.
10 Best Biotech Stocks Under $10 to Buy
According to Eli Casdin, CEO of Casdin Capital, biotech is currently experiencing a momentary stop despite being in one of the best economic environments in years.
13 Best Growth Stocks to Buy Right Now
On March 16, Chief Investment Strategist at Hightower Stephanie Link and Chief Investment Officer at NFJ Investment Group John Mowrey joined CNBC to discuss oil shocks and market opportunities.
Palisade Bio (PALI) Soars 5% Ahead of Clinical Trial Results
Palisade extended its winning streak to a fourth straight day on Wednesday, jumping 5.26 percent to close at $2.20 apiece as investors loaded portfolios ahead of the results of its clinical trial for ...
10 Penny Stocks to Buy in December
Trade in penny stocks, especially in Over-the-Counter (OTC) markets, has exploded this year as a retail investor boom and a record surge in prices of cryptocurrencies propels trading volume in such securities...
Hedge Fund Resource Center